Precigen (PGEN) AI Stock Analysis

• Market Cap: $551.25M
• Dividend Yield: N/A
• Average Volume (3M): 2.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: -1.12%
• EPS Growth: 20.77%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 297,972,930
• 10 Day Avg. Volume: 2,681,856
• 30 Day Avg. Volume: 2,851,708
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 91.53
• Enterprise Value/Gross Profit: -1.14K
• Enterprise Value/Ebitda: -3.26
• 1Y Price Target: $5.33
• Price Target Upside: 188.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $1.50 ▼(-18.92% Downside)

Precigen's overall stock score reflects significant financial challenges, with weak financial performance being the most critical factor. While technical analysis shows some positive momentum, the valuation remains unattractive due to ongoing losses. Recent corporate events provide some optimism, but the high-risk financial profile limits the overall score.

Positive Factors

Commercialization Strategy

Precigen is working with Eversana, an expert in commercialization of rare disease therapies, for the launch of PRGN-2012.

Manufacturing Capacity

Precigen has increased the manufacturing capacity at its GMP facilities to produce the drug for a successful commercial campaign upon approval.

Regulatory Approval

The FDA has accepted the BLA for PRGN-2012 as a treatment for recurrent respiratory papillomatosis (RRP) and set a PDUFA date, indicating a smooth approval process.

Negative Factors

Commercial Launch Challenges

Commercial adoption if approved will take time, with only one site at the NIH experienced in administering the treatment, and critical factors like cold chain storage and cost-related barriers to consider.

Financial Performance

For FY24, Precigen reported total revenue of $3.9M and a net loss of $0.47 per share, compared to the consensus estimated revenue of $4.1M and a net loss of $0.46 per share.

Regulatory Risk

There is regulatory risk with the current form of clinical data being single-arm and single investigator, and the ongoing confirmatory trial also being a single-arm study.

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

How the Company Makes Money

Precigen generates revenue through a combination of product sales, partnerships, and collaborations with pharmaceutical companies. The company derives income from licensing its proprietary technology platforms to other firms, as well as from milestone payments and royalties associated with the development and commercialization of its therapies. Significant partnerships, particularly those with major pharmaceutical players, enhance its revenue potential by providing access to broader markets and resources for research and development. Additionally, Precigen may receive funding through government grants and contracts aimed at advancing innovative therapies.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is severely weak, with declining revenues, negative profit margins, and financial instability. The income statement shows significant operational losses, the balance sheet reflects negative equity and high liabilities, and cash flow analysis indicates reliance on external financing.

Income Statement

Precigen's income statement reflects significant challenges with declining revenues and negative profit margins. The gross profit margin is negative at -2.17% TTM, indicating costs exceed sales. The net profit margin is also severely negative at -3728.79% TTM, showing substantial losses. Revenue has decreased drastically over recent periods, with a TTM revenue growth rate of -32.56%. EBIT and EBITDA margins are also negative, highlighting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows financial instability, with negative stockholders' equity of -$14.06 million TTM, indicating liabilities exceed assets. The debt-to-equity ratio isn't applicable due to negative equity, but the presence of high total liabilities of $142.85 million suggests significant leverage. The equity ratio is negative, further emphasizing the weak financial position. Return on equity is not applicable due to negative equity.

Cash Flow

Cash flow analysis shows continuous negative free cash flow, with a slight improvement in operating cash flow. Free cash flow growth rate is slightly positive at 1.95% TTM, but remains negative overall at -$75.26 million. The operating cash flow to net income ratio is 0.45 TTM, reflecting some operational cash generation despite losses. However, the company is heavily reliant on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.34M	3.92M	6.22M	26.91M	14.27M	103.18M
Gross Profit	-348.00K	-342.00K	-4.74M	20.57M	45.49M	47.66M
EBITDA	-121.97M	-123.50M	-89.23M	-66.00M	-84.07M	-70.41M
Net Income	-124.50M	-126.23M	-95.90M	28.32M	-92.17M	-170.52M
Balance Sheet
Total Assets	101.90M	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	59.75M	97.91M	62.85M	55.95M	108.66M	100.12M
Total Debt	5.15M	5.50M	7.10M	51.42M	190.07M	182.28M
Total Liabilities	107.79M	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	-36.78M	66.73M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-68.19M	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-66.28M	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-59.71M	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	108.09M	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Positive. The current price of 1.85 is above the 20-day moving average (MA) of 1.73, above the 50-day MA of 1.64, and above the 200-day MA of 1.38, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.71 is Neutral, neither overbought nor oversold. The STOCH value of 57.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGTX	54 Neutral	$669.44M	―	-379.53%	―	203.23%	-80.71%
PGEN	52 Neutral	$551.25M	―	-668.03%	―	-1.12%	20.77%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
RLAY	45 Neutral	$584.47M	―	-46.24%	―	-76.27%	22.77%
TYRA	41 Neutral	$569.00M	―	-27.04%	―	―	3.01%
MNMD	40 Neutral	$739.57M	―	-59.11%	―	―	39.66%
SANA	33 Underperform	$701.48M	―	-109.12%	―	―	7.58%

Precigen Corporate Events

Precigen Announces Key Approvals at Annual Meeting

At the Annual Meeting of Stockholders on June 26, 2025, Precigen, Inc. announced several key approvals, including an amendment to increase the shares available under its 2023 Omnibus Incentive Plan by 11.5 million. Additionally, stockholders approved increasing the company’s authorized shares of common stock by 300 million and ratified Deloitte & Touche LLP as the independent accounting firm for 2025. These decisions are expected to impact Precigen’s operational flexibility and shareholder value positively.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.